Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Instagram Outage Disrupts Thousands of U.S. Users 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FREDERICK, MD, Jan. 16, 2018 -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of an independent clinical study to investigate the efficacy of the Allay® Menstrual Pain device. The study will be take place at the prestigious United Kingdom Birmingham Women's NHS Foundation Trust.
Primary dysmenorrhea (menstrual pain) is the most common women’s health problem. 28% of women are in the menstruating phase of life and 60% have monthly pain and discomfort that can negatively impact work productivity, cognitive performance, and quality of life. Allay Menstrual Pain Therapy provides drug free affordable 24-hour relief for less than $1.00 per day.
The principal investigator is Professor T. Justin Clark, MD (hons) FRCOG. Dr. Clark and his team are renowned researchers in women’s health. This expanded menstrual pain study will involve 60 women who currently suffer with menstrual pain, and is designed to span two menstruation cycles for each subject. Enrollment has been completed and the study is expected to be finished in August of this year. The results will also be used to support a grant funding application in the United Kingdom to conduct a larger multi-center clinical study. Additional details about the study can be found at the NIH’s clinical trials listing page: https://clinicaltrials.gov/ct2/show/NCT03394547?cond=Menstrual+Pain&cntry=GB&rank=1
“Women should have safe, drug-free menstrual pain therapy options like the nonprescription Allay in view of the growing evidence on the side effects of over-the-counter and prescription pain medications. This UK randomized, double-blinded placebo-controlled trial will allow us to gain US FDA market clearance, broader market acceptance, and a better understanding of the mechanism of action for this product”, said Dr. Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit us at www.bielorp.com
Contact: Paul Knopick 940 262 3584 [email protected]
